因文蒂瓦

最新新闻

• 评级变动
  A Quick Look at Today's Ratings for Inventiva(IVA.US), With a Forecast Between $12 to $20
  \u5e02\u573a\u8d44\u8baf · 2026/4/2
• 评级变动
  TD Cowen Maintains Inventiva(IVA.US) With Buy Rating, Maintains Target Price $10
  \u5e02\u573a\u8d44\u8baf · 2026/6/10
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Inventiva (IVA), Rhythm Pharmaceuticals (RYTM) and Belite Bio, Inc. ADR (BLTE)
  TipRanks · 2026/6/15
• 评级变动
  Cantor Fitzgerald Initiates Inventiva(IVA.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/7/17
• 评级变动
  A Quick Look at Today's Ratings for Inventiva(IVA.US), With a Forecast Between $11 to $15
  \u5e02\u573a\u8d44\u8baf · 2026/4/1
• UBS Maintains Inventiva(IVA.US) With Buy Rating, Maintains Target Price $12
  \u5e02\u573a\u8d44\u8baf · 2026/9/30
• 评级变动
  Truist Financial Maintains Inventiva(IVA.US) With Buy Rating, Announces Target Price $13
  \u5e02\u573a\u8d44\u8baf · 2026/7/27
• 评级变动
  Barclays Maintains Inventiva(IVA.US) With Buy Rating, Maintains Target Price $18
  \u5e02\u573a\u8d44\u8baf · 2026/6/4
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Inventiva (IVA), MAIA Biotechnology, Inc. (MAIA) and Palvella Therapeutics (PVLA)
  TipRanks · 2026/4/1
• A Quick Look at Today's Ratings for Inventiva(IVA.US), With a Forecast Between $10 to $21
  \u5e02\u573a\u8d44\u8baf · 2026/9/29
• 评级变动
  Guggenheim Maintains Inventiva(IVA.US) With Buy Rating, Raises Target Price to $14
  \u5e02\u573a\u8d44\u8baf · 2026/9/15
• Truist Financial Maintains Inventiva(IVA.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/10/2
• A Quick Look at Today's Ratings for Inventiva(IVA.US), With a Forecast Between $12 to $21
  \u5e02\u573a\u8d44\u8baf · 2026/9/30
• 评级变动
  LifeSci Capital Maintains Inventiva(IVA.US) With Buy Rating, Maintains Target Price $14
  \u5e02\u573a\u8d44\u8baf · 2026/3/28
• 评级变动
  Guggenheim Maintains Inventiva(IVA.US) With Buy Rating, Maintains Target Price $11
  \u5e02\u573a\u8d44\u8baf · 2026/5/27
• Stifel Maintains Inventiva(IVA.US) With Buy Rating, Maintains Target Price $15
  \u5e02\u573a\u8d44\u8baf · 2026/9/23
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Inventiva (IVA), Neumora Therapeutics, Inc. (NMRA) and Gain Therapeutics (GANX)
  TipRanks · 2026/3/31
• 评级变动
  Analysts Conflicted on These Healthcare Names: BrightSpring Health Services, Inc. (BTSG), Inventiva (IVA) and Moderna (MRNA)
  TipRanks · 2026/8/3
• 评级变动
  Piper Sandler Maintains Inventiva(IVA.US) With Buy Rating, Maintains Target Price $26
  \u5e02\u573a\u8d44\u8baf · 2026/9/17
• 评级变动
  Truist Financial Maintains Inventiva(IVA.US) With Buy Rating, Maintains Target Price $13
  \u5e02\u573a\u8d44\u8baf · 2026/3/19

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。